Prednisone
- Generic Name
- Prednisone
- Brand Names
- Deltasone, Rayos, Winpred
- Drug Type
- Small Molecule
- Chemical Formula
- C21H26O5
- CAS Number
- 53-03-2
- Unique Ingredient Identifier
- VB0R961HZT
- Background
A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.
Prednisone was granted FDA approval on 21 February 1955.
- Indication
Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.
- Associated Conditions
- Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis
- Associated Therapies
- Palliative Treatment
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
Phase 2
Recruiting
- Conditions
- Angioimmunoblastic T-cell LymphomaEnteropathy-Associated T-Cell LymphomaFollicular T-Cell LymphomaMature T-Cell and NK-Cell Non-Hodgkin LymphomaMonomorphic Epitheliotropic Intestinal T-Cell LymphomaNodal Peripheral T-Cell Lymphoma With TFH PhenotypePeripheral T-Cell Lymphoma, Not Otherwise Specified
- Interventions
- First Posted Date
- 2021-03-17
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 170
- Registration Number
- NCT04803201
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸Memorial Hospital East, Shiloh, Illinois, United States
🇺🇸University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania, United States
Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma
Phase 2
Recruiting
- Conditions
- Ann Arbor Stage III Diffuse Large B-Cell LymphomaAnn Arbor Stage IIX (Bulky) Diffuse Large B-Cell LymphomaAnn Arbor Stage IV Diffuse Large B-Cell LymphomaHigh Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsPrimary Cutaneous Diffuse Large B-Cell Lymphoma, Leg TypeT-Cell/Histiocyte-Rich Large B-Cell LymphomaDiffuse Large B-Cell Lymphoma Activated B-Cell TypeDiffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedEBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedHigh Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements
- Interventions
- First Posted Date
- 2021-03-16
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 422
- Registration Number
- NCT04799275
- Locations
- 🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States
🇺🇸Banner University Medical Center - Tucson, Tucson, Arizona, United States
🇺🇸Kaiser Permanente-Anaheim, Anaheim, California, United States
Corticosteroids for COVID-19
Phase 3
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2021-03-12
- Last Posted Date
- 2022-04-14
- Lead Sponsor
- University of Alberta
- Registration Number
- NCT04795583
- Locations
- 🇨🇴
Clinica de la Mujer, Bogotá, Colombia
🇲🇽ABC Medical Center, Mexico City, Mexico
A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2021-03-10
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 50
- Registration Number
- NCT04790903
- Locations
- 🇫🇷
Centre Hospitalier Régional Universitaire de Lille (CHRU) - Hôpital Claude Huriez, Lille, France
🇫🇷CHU Montpellier - Saint ELOI, Montpellier, France
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
The Impact of Prednisone on Semen Parameters and Pregnancy Rates Post Vasectomy Reversal
- First Posted Date
- 2021-03-09
- Last Posted Date
- 2023-09-13
- Target Recruit Count
- 100
- Registration Number
- NCT04788823
- Locations
- 🇺🇸
Cure PD, Orem, Utah, United States
A 3 Arm Randomized Study on Health-related QoL of Elderly Patients With Advanced Soft Tissue Sarcoma
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2021-03-03
- Last Posted Date
- 2024-02-22
- Target Recruit Count
- 14
- Registration Number
- NCT04780464
- Locations
- 🇯🇴
King Hussein Cancer Center, Amman, Jordan
🇨🇾Bank Of Cyprus Oncology Centre, Nicosia, Cyprus
PROUD Study - Preventing Opioid Use Disorders
Phase 4
Terminated
- Conditions
- Interventions
- Behavioral: Guided mindfulness exercisesOther: Self-administered aromatherapyDrug: Baby aspirinDrug: Tylenol/AcetaminophenDrug: PregabalinDrug: PrednisoneDrug: MeloxicamDrug: PrilosecDrug: TramadolDrug: VoltarenDrug: ZofranDrug: PepcidDrug: ReglanDrug: VersedDrug: LidocaineDrug: PropofolDrug: AncefDrug: Tranexamic Acid (TXA)Drug: DecadronDrug: Bupivacaine hydrochlorideDrug: Toradol
- First Posted Date
- 2021-02-23
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Emory University
- Target Recruit Count
- 57
- Registration Number
- NCT04766996
- Locations
- 🇺🇸
Emory University Orthopaedic and Spine Hospital, Atlanta, Georgia, United States
Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
Phase 3
Recruiting
- Conditions
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Computed TomographyDrug: CyclophosphamideDrug: Doxorubicin HydrochlorideProcedure: EchocardiographyDrug: Etoposide PhosphateBiological: FilgrastimProcedure: Lumbar PunctureBiological: PegfilgrastimBiological: NivolumabProcedure: Positron Emission TomographyRadiation: Radiation TherapyDrug: PrednisoloneDrug: PrednisoneBiological: RituximabBiological: Rituximab and Hyaluronidase HumanDrug: Vincristine Sulfate
- First Posted Date
- 2021-02-18
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 244
- Registration Number
- NCT04759586
- Locations
- 🇺🇸
Valley Children's Hospital, Madera, California, United States
🇺🇸Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸USA Health Strada Patient Care Center, Mobile, Alabama, United States
DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
Phase 1
Completed
- Conditions
- Recurrent Chronic Myelomonocytic LeukemiaHematopoietic and Lymphoid Cell NeoplasmRecurrent Acute Myeloid LeukemiaRecurrent Acute Lymphoblastic LeukemiaRecurrent Myelodysplastic SyndromeRefractory Acute Lymphoblastic LeukemiaRefractory Acute Myeloid LeukemiaRefractory Chronic Myelomonocytic LeukemiaRefractory Myelodysplastic Syndrome
- Interventions
- First Posted Date
- 2021-02-12
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 17
- Registration Number
- NCT04752163
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)
- First Posted Date
- 2021-02-10
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 29
- Registration Number
- NCT04748042
- Locations
- 🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath